ReviewDigestive diseases and sciences2026
Management of Refractory Hepatic Encephalopathy.
Review in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Refractory hepatic encephalopathy (HE) is a complex and debilitating disorder that significantly impacts healthcare utilization and causes lingering cognitive defects that can at times be permanent. It represents an economically and emotionally costly entity for patients and caregivers. Precipitants and pathogenic factors of this disease are numerous, cumulative, and often present with subtle features. A systematic approach to management should include a thorough evaluation of medication adherence, identification of precipitating factors, consideration of a rare disease called acquired hepatocerebral degeneration in patients with pyramidal symptoms, and assessment for both iatrogenic and spontaneous portosystemic shunts. Second-line treatments may include branched-chain amino acids, zinc supplementation, probiotics, and shunt embolization procedures, which have demonstrated significant improvements in HE episodes and hospitalizations. Strong clinical acumen and a systematic approach are essential for improving outcomes in this challenging patient population with refractory HE.
Indexed as
Identifiers
41350964What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.